{'fraction_non_alphanumeric': 0.03811659192825112, 'fraction_numerical': 0.014947683109118086, 'mean_word_length': 6.397790055248619, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Strength in Complementary Weaknesses: An Effective Dual Specificity Antibody Approach against Ovarian Cancer

Ovarian cancer (OvCa) is the most lethal of gynecological diseases and is known for chemoresistance and frequent reoccurrence with no effective treatment available(1). Therefore, developing safe and efficacious therapies that improve long‐term progression free survival remains an urgent unmet medical need. Recent clinical data indicates that immune system activating antibodies (mono‐specific or bispecific) are highly effective in chemoresistant blood cancer and melanoma patients(2–5). However, in the solid tumors of epithelial origin, including high‐grade serous ovarian carcinomas, antibody‐based approaches have not produced similar clinical outcomes. One major roadblock to the success of therapeutic antibodies in solid cancers is the ineffective penetration of the immune effector cells into the sturdy tumor bed(6, 7), a requisite for the natural killer cell‐mediated antibody‐directed cell cytotoxicity (ADCC) and killer T‐cell‐mediated cytotoxicity (8–10). In support, various solid epithelial cancer approved antibodies targeted against receptor tyrosine kinases have also indicated that ADCC contribution is not a major part of their efficacy in breast(11–14), colorectal(15–17), renal(18), and lung cancers(19).